about
Associative sequence learning in humans[Pharmacotherapy of central oculomotor disorders].A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxiasNo short-term effects of calorie-controlled Mediterranean or fast food dietary interventions on established biomarkers of vascular or metabolic risk in healthy individuals.Real-time computer-based visual feedback improves visual acuity in downbeat nystagmus - a pilot study.The effect of zoledronic acid on the fracture risk in men with osteoporosis.Distinguishing in-hospital and out-of-hospital status epilepticus: clinical implications from a 10-year cohort study.Emergency response to out-of-hospital status epilepticus: A 10-year observational cohort study.Preventing road injuries in children by applying feedback devices.[Male osteoporosis].Considering a possible application to prevent or to treat arterial stiffness.Community-based applications to enhance road safety.Dalfampridine in patients with downbeat nystagmus--an observational study.The intensity of downbeat nystagmus during daytime.Group effort in resuscitation teams.Treatment of dizziness: an interdisciplinary update.Dizziness in the emergency department: an update on diagnosis.A left-hand superiority for the implicit detection of a rule.Tackling submission and publication bias.Ginkgo biloba extract EGb 761® alleviates neurosensory symptoms in patients with dementia: a meta-analysis of treatment effects on tinnitus and dizziness in randomized, placebo-controlled trials.Head position during resting modifies spontaneous daytime decrease of downbeat nystagmusAminopyridine treatment in a patient with bilateral vestibular failure and cryptogenic downbeat nystagmusAdaptive motion processing in bilateral vestibular failureComparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmusLetter: lack of association between MDR1 polymorphisms and pharmacoresistance to anticonvulsive drugs in patients with childhood-onset epilepsyLetter by Spiegel et al regarding article, "net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study"Reasons to recommend lifestyle changes in type 2 diabetes mellitus and obesityA randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptomsReducing health risks of physical inactivity by cardiac rehabilitationExplanations for the 'smoker's paradox' in cardiac resuscitationAssociations between periodic social events and status epilepticus-An 11-year cohort studyVenovenous extracorporeal membrane oxygenation to treat hypercapnia in a morbidly obese patientUntangling operational failures of the Status Epilepticus Severity Score (STESS)Aspirin as a painkiller in patients with a high cardiovascular risk profile
P50
Q28236258-86EAFCC9-F0A1-4E4F-9585-D783CAFCA513Q31162966-D174473C-D3D5-4D56-AE02-459D8F98D177Q35104451-FACE43F1-4F20-4D1B-9D09-3DCF080245E9Q35308131-9B4CFDCB-C8D9-4D3B-AC8F-4639109B6214Q36428360-B509D936-9295-4134-B9A5-0992700F2DEFQ38182950-9EE114F9-ED89-4D39-941E-88540FF415F4Q38670344-37C1B6E3-DDB3-460A-8F65-5B16133A5102Q38703875-D3974AA8-34AA-42EA-95D1-BB55B7E6EE8CQ39665194-67FDB566-3169-479B-910C-FE458964E1F6Q40780710-3D11AC3C-78EE-4F7E-A7EF-1CB65061F309Q43634785-B0EEAAB4-3F95-44D5-9DC5-48976549034BQ44101663-B288A4C2-EFD7-4FF1-ABCC-B06790C13A2CQ44494542-A1280F52-F079-424F-B5F9-C9D56923F515Q46658985-40BDE27E-035E-4525-BF8C-A2E9AB480E64Q49077304-8B94E65F-88F5-4044-AB2A-FC9601592A1BQ49544208-3533D4C0-B99A-4DE4-A451-0567B411ADB6Q49544236-DFDB3D53-0302-4F46-84DF-7CFD3E3584D5Q50260370-8EF5F904-B167-4157-A333-8BA39876BCC3Q53250730-35761361-5148-4D75-A08C-15E0B6DF444FQ55408994-21E58A14-5183-4BBE-A277-F671F36D4258Q82560780-11F3B0DB-3116-49FF-88A0-A0E8B53DAD3FQ83841011-2DCBA34C-ECAA-4954-BCA3-98FEB8A2625CQ84062718-4172BAA3-DEBE-4693-A9D0-13C0D2CA973EQ84513554-5825E1A1-A69A-4F71-A1A9-53936251CBD8Q85012500-E5F75DFD-1772-4635-BA78-C97230154074Q85420664-21673C64-C9A7-4410-BF17-5A40E05EF238Q85989585-63794111-D7D7-4950-8C8D-F54CF60E6E3BQ87023050-09F504EF-4AE4-4AB6-BC9A-7E9442D66974Q87417585-988907E6-8ACF-429F-BC46-64C774CFDD3AQ87465425-1C3C10B9-934F-41B7-9743-2B7A94356B70Q88811787-35FE8600-3BDE-44CB-B211-AB94A40698AAQ90465373-F15E750B-42D7-4342-8453-9894F06152C6Q92657778-33C94427-FC6E-4A19-ACEE-ACC296796405Q96023024-A4375E90-17C8-47AB-A9C9-B9F9181803C1
P50
description
researcher ORCID ID = 0000-0002-3693-2120
@en
name
Rainer Spiegel
@ast
Rainer Spiegel
@en
Rainer Spiegel
@es
Rainer Spiegel
@nl
type
label
Rainer Spiegel
@ast
Rainer Spiegel
@en
Rainer Spiegel
@es
Rainer Spiegel
@nl
prefLabel
Rainer Spiegel
@ast
Rainer Spiegel
@en
Rainer Spiegel
@es
Rainer Spiegel
@nl
P31
P496
0000-0002-3693-2120